Lipitor

Phase 2Small molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lipitor is one of 97 small molecule programs targeting Kidney Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Dialysis PatientsCompleted

Magnetic Resonance ImagingTerminated

ToxicityRecruiting

Kidney TransplantPreclinical

Active, not recruiting

Dialysis PatientsPreclinical

Completed

Magnetic Resonance ImagingPreclinical

Terminated

ToxicityPhase 2

Recruiting

Competition

Competitive Landscape

121 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Phase 3

1 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 3

Felzartamab

Biogen

Phase 3

1 4

Biological/vaccine

Vertex Pharmaceuticals

Phase 3

1 5

Envarsus XR

UUniversity of Wisconsin, Madison

Phase 3

2 6

Cytogam

JJohns Hopkins University

Phase 3

2 7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 8

Zemplar

AbbVie

Preclinical

2 9

Cysteine Hydrochloride

Novartis

Preclinical

1 10

Sensipar

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Toxicity

NCT05559164

Clinical

Trials by Indication[1]

Atorvastatin2 trials

Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy

Completed·QQueen's University··NCT00299884·45 enrolled

Bioavailability Study for New Atorvastatin Formulation

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00844376·12 enrolled

Pediatric1 trial

Bioequivalence Study On Pediatric Appropriate Formulation

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT00777517·76 enrolled

Mitochondria1 trial

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

Completed·UUniversity of Kansas Medical Center·Phase 4·NCT03351998·68 enrolled

Exercise1 trial

Impact of Statin Therapy on Adaptations to Aerobic Exercise

Completed·UUniversity of Kansas Medical Center·Phase 4·NCT03360916·52 enrolled

Toxicity1 trial

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05559164·60 enrolled

5 more indications

Kidney Transplant1 trial

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00023231·35 enrolled

Polycystic Ovary Syndrome1 trial

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

Completed·MMilton S. Hershey Medical Center·Phase 2·NCT00529542·20 enrolled

Dialysis Patients1 trial

Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients

Completed·HHormozgan University of Medical Sciences·N/A·NCT01305317·74 enrolled

Magnetic Resonance Imaging1 trial

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

Terminated·JJohns Hopkins University·N/A·NCT00770679·16 enrolled

Hypercholesterolemia1 trial

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

Completed·OOrient Pharma Co., Ltd.·Phase 3·NCT01710007·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lipitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lipitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Atorvastatin2 trials

Pediatric1 trial

Mitochondria1 trial

Exercise1 trial

Toxicity1 trial

Kidney Transplant1 trial

Polycystic Ovary Syndrome1 trial

Dialysis Patients1 trial

Magnetic Resonance Imaging1 trial

Hypercholesterolemia1 trial

References

Drug Info

Quick Facts

Related News